Perrigo should have enough on current facility to acquire HRA Pharma

Chicago, Sept. 8 – Perrigo Co. plc announced that the company should have enough capacity on its credit facility for its upcoming acquisition of Hera SAS that is valued at €1.8 billion, according to a press release.

The company expects to acquire the company on a cash-free, debt-free basis.

However, Perrigo did not that if market conditions were favorable, it might consider new debt financing.

The transaction is expected to close by the end of the first half of 2022.

Based in Dublin, Perrigo manufactures and markets over-the-counter drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.